Stock analysts at Deutsche Bank initiated coverage on shares of Incyte (NASDAQ:INCY) in a report issued on Tuesday, The Fly reports. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on INCY. Argus restated a “buy” rating and issued a $150.00 price objective on shares of Incyte in a research report on Wednesday, September 13th. J P Morgan Chase & Co restated a “buy” rating on shares of Incyte in a research report on Wednesday, October 25th. Goldman Sachs Group started coverage on shares of Incyte in a research report on Friday, October 6th. They issued a “buy” rating and a $160.00 price objective for the company. Jefferies Group restated a “buy” rating on shares of Incyte in a research report on Friday, October 6th. Finally, Cowen restated a “buy” rating on shares of Incyte in a research report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $145.65.

Incyte (NASDAQ INCY) traded down $1.85 during trading hours on Tuesday, hitting $95.40. 1,548,638 shares of the stock were exchanged, compared to its average volume of 1,906,698. Incyte has a 52 week low of $92.91 and a 52 week high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.11. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The company had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. Incyte’s quarterly revenue was up 41.6% compared to the same quarter last year. sell-side analysts anticipate that Incyte will post -1.33 EPS for the current year.

In other Incyte news, EVP Barry P. Flannelly sold 714 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $124.25, for a total transaction of $88,714.50. Following the completion of the sale, the executive vice president now owns 15,496 shares in the company, valued at approximately $1,925,378. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Herve Hoppenot sold 70,502 shares of the company’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $119.45, for a total transaction of $8,421,463.90. The disclosure for this sale can be found here. Insiders have sold a total of 104,334 shares of company stock valued at $11,992,011 in the last quarter. Corporate insiders own 17.70% of the company’s stock.

Several institutional investors have recently modified their holdings of INCY. Vanguard Group Inc. raised its position in shares of Incyte by 11.1% during the 2nd quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock valued at $2,156,276,000 after acquiring an additional 1,709,685 shares during the last quarter. Manning & Napier Advisors LLC acquired a new position in shares of Incyte in the 3rd quarter valued at $125,065,000. Janus Henderson Group PLC grew its holdings in shares of Incyte by 4,570.1% in the 2nd quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock valued at $131,622,000 after buying an additional 1,022,979 shares during the period. Old Mutual Global Investors UK Ltd. grew its holdings in shares of Incyte by 374.4% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 930,319 shares of the biopharmaceutical company’s stock valued at $108,605,000 after buying an additional 734,235 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Incyte by 64.1% in the 2nd quarter. Jennison Associates LLC now owns 1,313,982 shares of the biopharmaceutical company’s stock valued at $165,443,000 after buying an additional 513,423 shares during the period. Institutional investors own 90.86% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/12/incyte-incy-now-covered-by-deutsche-bank.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

The Fly

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.